Q3 earnings and guidance change the conversation
Establishment Labs Holdings (ESTA) put fresh numbers on the table with its third quarter 2026 report, pairing higher sales and a narrower loss with its first positive operating and free cash flow.
At a share price of US$68.41, Establishment Labs Holdings has seen a 7.7% 7 day share price return and a 7.4% 30 day share price return. However, the 90 day share price performance is down 26.1%, while the 1 year total shareholder return is 34.4%. This points to momentum rebuilding after a weaker stretch, as the earnings beat, higher guidance and the shift to positive cash generation have reset how investors are weighing both growth potential and risk.
Scan for other healthcare specialists showing similar cash flow and guidance momentum with our curated list of list of solid balance sheet and fundamentals (23 results)
Establishment Labs Holdings has just reported a strong quarter and raised its guidance, yet the share price is still rebuilding after a sharp 90 day pullback. Is this an entry point worth considering now, or one to wait on until the valuation looks clearer?
Most Popular Establishment Labs Holdings Narrative: 33% Undervalued
Analysts following Establishment Labs Holdings see fair value at about $102.44 per share, compared with the latest close at $68.41. This price difference puts a spotlight on the growth story that needs to play out to close that gap.
Accelerating surgeon adoption and utilization curve in the U.S., combined with further account additions and growing patient demand (amplified by patient-driven requests and social media engagement), positions the company for continued strong revenue growth and sustainable market share gains in a large, culturally receptive, and increasingly affluent market.
See why 1 investors see Establishment Labs Holdings as 33% undervalued.
Result: Fair Value of $102.44 (UNDERVALUED)
Still, the Establishment Labs Holdings story could be knocked off course if high SG&A and R&D costs persist, or if product concentration risk bites.
Find out about the key risks to this Establishment Labs Holdings narrative.
Another way to look at Establishment Labs Holdings’ valuation
The analyst fair value of $102.44 paints Establishment Labs Holdings as undervalued, yet the current P/S of 8.3x tells a different story. That figure is well above the fair ratio of 5.1x, the US Medical Equipment industry at 2.7x, and peers at 2.2x. In practice, that gap could mean you are paying up today for execution that still needs to be proved out.
Before leaning too hard on any single metric, it can help to see how all the underlying numbers shape that price to sales view in context. This is where the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
If the mixed signals in Establishment Labs Holdings so far have you on the fence, that hesitation is useful information in itself. Act quickly on your questions by stress testing the upside case directly through the 3 key rewards.
Looking for more investment ideas beyond Establishment Labs Holdings?
Do not stop with Establishment Labs Holdings. Use the same disciplined mindset here to hunt for fresh opportunities that match your risk, income, and growth goals.
- Target dependable income streams by reviewing companies that show strong yields and resilience in our 7 dividend fortresses.
- Hunt for quality at a reasonable price by scanning stocks flagged as potentially mispriced in the 30 high quality undervalued stocks.
- Prioritize capital protection first by filtering for companies with stronger risk profiles through the 30 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com